Acadia Pharma (ACAD) Misses Q3 EPS by 5c

Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $2.9 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• The LGL Group (LGL) Misses Q2 EPS by 8c